Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer-Reference-Cited by-同舟云学术

Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer

Published:2024-07-14 Issue: Volume: Page:
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Johnson Hannah¹^ORCID,Singh Amandeep¹,Raza Asif¹^ORCID,Sha Congzhou M.¹^ORCID,Wang Jian¹^ORCID,Gowda Krishne¹,Shen Zhihang²,Nair Haritha³,Li Chenglong²,Dokholyan Nikolay V.¹^ORCID,Narayan Satya³,Sharma Arun K.¹^ORCID

Affiliation:

1. Department of Pharmacology, Penn State Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, United States

2. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1345 Center Drive, Gainesville, Florida 32610, United States

3. Department of Anatomy and Cell Biology, College of Medicine, University of Florida, 1200 Newell Drive, Gainesville, Florida 32610, United States

Funder

Penn State College of Medicine

Penn State Hershey Cancer Institute

PA Tobacco Settlement Fund

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c01077

Reference31 articles.

1. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors

2. Cancer statistics, 2024

3. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin

4. RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer

5. 5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes